Study on Colchicine for Patients with Angina Symptoms and Coronary Microvascular Disease

2 1 1

What is this study about?

This clinical trial is focused on studying a condition known as Coronary Microvascular Disease (CMD), which affects the small blood vessels in the heart and can cause chest pain, known as angina, even when larger coronary arteries are not blocked. The study will explore the effects of a medication called Colchicine, which is commonly used to treat inflammation, on improving blood flow in these small vessels. Participants in the study will receive either Colchicine 500 microgram Tablets or a placebo, which looks like the medication but does not contain the active ingredient.

The purpose of the study is to see if Colchicine can improve blood flow in the heart and reduce symptoms in patients with CMD. The study will last for about six months. During this time, participants will undergo various assessments, including heart scans, to measure changes in blood flow and symptom questionnaires to evaluate any changes in their angina symptoms. The study will also look at how Colchicine affects certain proteins and functions in the blood vessels.

In addition to Colchicine, the study will involve the use of Regadenoson and Adenosine, which are substances used to stress the heart during certain tests, and local anesthetics, which are used to numb specific areas of the body. These substances will help researchers better understand the effects of Colchicine on heart function and blood flow. The study aims to provide valuable insights into potential new treatments for CMD and improve the quality of life for those affected by this condition.

1 joining the trial

Upon joining the clinical trial, you will be informed about the study’s purpose, procedures, and your role as a participant. You will be asked to provide informed consent, which means you agree to participate after understanding all aspects of the trial.

2 initial assessment

You will undergo an initial assessment to confirm eligibility. This includes a test called [15O]H2O-PET-scan to measure your myocardial blood flow reserve (MBFR) and hyperemic myocardial blood flow (hMBF). These tests help determine if you have coronary microvascular disease (CMD) without obstructive coronary artery disease (CAD).

3 medication administration

If eligible, you will be assigned to receive either Colchicine 500 microgram Tablets or a placebo. A placebo is a substance with no active medication, used to compare effects. You will take the assigned tablets orally, as directed by the study team.

4 ongoing monitoring

Throughout the trial, you will have regular check-ups to monitor your health and any changes in symptoms. You may be asked to complete questionnaires, such as the Seattle Angina Questionnaire, to assess symptom burden.

5 follow-up assessments

After six months, you will undergo another [15O]H2O-PET-scan to assess changes in your myocardial blood flow reserve and hyperemic myocardial blood flow. This helps evaluate the effect of the treatment.

6 study completion

Once the trial period is over, you will have a final assessment to review your overall health and any changes observed during the study. The study team will discuss the results with you and provide any necessary follow-up care.

Who Can Join the Study?

Must have CMD (Coronary Microvascular Disease), which means the small blood vessels in the heart are not working properly.
Must have a myocardial blood flow reserve (MBFR) of less than 2.5 or a hyperemic myocardial blood flow (hMBF) of less than 2.3 ml/g/min. These are measures of how well blood flows through the heart.
Must not have obstructive CAD (Coronary Artery Disease), which means there are no blockages in the main heart arteries, as determined by a special heart scan called [15O]H2O-PET.
Must be within the age range of 18 to 65 years old.
Both males and females can participate.
Participants should not be from a vulnerable population, meaning they should not be in a situation that makes them more at risk or in need of special protection.

Who Cannot Join the Study?

Patients with other serious heart conditions that are not related to coronary microvascular disease (CMD) cannot participate.
Individuals who have had a heart attack or stroke in the last 6 months are excluded.
Patients with severe liver or kidney disease are not eligible.
People with uncontrolled high blood pressure cannot join the study.
Individuals with a history of severe allergic reactions to medications are excluded.
Pregnant or breastfeeding women cannot participate.
Patients currently participating in another clinical trial are not eligible.
Individuals with any condition that the study doctors believe would make it unsafe for them to participate are excluded.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country	Status
Bispebjerg Hospital	Copenhagen	Denmark

Other Sites

No sites found in this category

Trial status

Country	Status	Recruitment Start
Denmark	Recruiting	01.02.2024

Trial locations

Investigated drugs:

Colchicine is a medication that is being studied for its potential to improve blood flow in the heart. It is often used to treat inflammation and is being tested to see if it can help people who have chest pain due to small blood vessels in the heart not working properly. The goal is to see if colchicine can help these blood vessels work better, which might reduce chest pain and improve heart health.

Investigated diseases:

Coronary Microvascular Disease – Coronary Microvascular Disease (CMD) is a condition affecting the small blood vessels in the heart. Unlike larger coronary artery disease, CMD involves the tiny arteries that branch off from the larger coronary arteries. These small vessels can become damaged or dysfunctional, leading to reduced blood flow to the heart muscle. The disease progresses as these microvessels fail to dilate properly, which can cause chest pain or angina, especially during physical exertion or stress. Over time, the impaired blood flow can lead to persistent symptoms and may affect heart function. CMD is often associated with other conditions like high blood pressure or diabetes, which can exacerbate the dysfunction of the microvessels.

Trial ID:

2023-507981-17-00

Protocol code:

2023-507981-17-00

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on Colchicine for Patients with Angina Symptoms and Coronary Microvascular Disease

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?